InnoCare Pharma Limited reported no changes to its share capital structure for April 2026, according to the company’s Monthly Return submitted to Hong Kong Exchanges and Clearing Limited on 7 May 2026.

Authorised and Issued Share Capital • Authorised share capital stayed at 25.00 billion ordinary shares with a par value of USD 0.000002 each, equivalent to USD 50,000. • Total issued shares were unchanged at 1.50 billion, comprising 1.49 billion shares in circulation and 2.49 million treasury shares. • The company also maintains 268.36 million ordinary shares listed on Shanghai’s STAR Market, with no movement during the month.

Public-Float Compliance InnoCare confirmed compliance with the Main Board’s minimum 25% public-float requirement as at 30 April 2026.

Equity Incentive Pool • 2023 RMB Share Incentive Scheme: A maximum of 8.95 million restricted shares had been approved; 828,250 shares have lapsed to date, leaving 4.41 million shares available for future grants. • 2024 RMB Share Incentive Scheme: A maximum of 12.34 million restricted shares had been approved; 235,000 shares have lapsed, leaving 9.64 million shares available. • 2023 Share Award Scheme: 51.48 million Hong Kong-listed shares are reserved for RSU grants, all previously issued; no new issuance required.

Overall, no new shares were issued, and no treasury shares were cancelled or re-allotted in April. InnoCare’s equity base and treasury share count remained steady, while the company retains flexibility to issue up to 14.04 million new RMB-denominated shares under existing incentive plans.